Y Intercept Hong Kong Ltd Purchases 73,242 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Y Intercept Hong Kong Ltd grew its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 106.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 141,865 shares of the biotechnology company's stock after acquiring an additional 73,242 shares during the period. Y Intercept Hong Kong Ltd owned 0.07% of BioCryst Pharmaceuticals worth $1,064,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. Allianz Asset Management GmbH lifted its holdings in BioCryst Pharmaceuticals by 9.6% during the 1st quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company's stock worth $103,000 after purchasing an additional 1,200 shares during the last quarter. Hussman Strategic Advisors Inc. acquired a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth $2,362,000. CWM LLC boosted its position in shares of BioCryst Pharmaceuticals by 167.5% in the first quarter. CWM LLC now owns 53,750 shares of the biotechnology company's stock valued at $403,000 after acquiring an additional 33,656 shares during the period. Cerity Partners LLC boosted its position in shares of BioCryst Pharmaceuticals by 203.6% in the first quarter. Cerity Partners LLC now owns 36,410 shares of the biotechnology company's stock valued at $273,000 after acquiring an additional 24,418 shares during the period. Finally, Allspring Global Investments Holdings LLC acquired a new position in shares of BioCryst Pharmaceuticals in the first quarter valued at about $79,000. Institutional investors own 85.88% of the company's stock.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $17.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, June 25th. Bank of America lifted their price target on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Tuesday, July 1st. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Cantor Fitzgerald started coverage on BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price objective for the company. Finally, JPMorgan Chase & Co. upped their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research report on Tuesday, May 6th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.70.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock remained flat at $8.55 during midday trading on Friday. The company's stock had a trading volume of 2,363,782 shares, compared to its average volume of 3,191,850. The firm has a market cap of $1.79 billion, a PE ratio of -32.88, a PEG ratio of 1.40 and a beta of 1.04. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.01 and a 1 year high of $11.31. The firm's 50 day moving average is $9.80 and its 200-day moving average is $8.70.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.